Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.

Abstract

PURPOSE ActivatingPIK3CAgenomic alterations are frequent in head and neck squamous cell carcinoma (HNSCC), and there is an association between phosphoinositide 3-kinase (PI3K) signaling and radioresistance. Hence, we investigated the therapeutic efficacy of inhibiting PI3K with GDC-0032, a PI3K inhibitor with potent activity against p110α, in combination… (More)
DOI: 10.1158/1078-0432.CCR-15-2245

Topics

Cite this paper

@article{Zumsteg2016TaselisibA, title={Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.}, author={Zachary S Zumsteg and Natasha Morse and Gabriel S. Krigsfeld and Gaorav P. Gupta and Daniel S. Higginson and Nancy Y. Lee and Luc G T Morris and Ian Ganly and Stephan L Shiao and Simon N. Powell and Christine H. Chung and Maurizio Scaltriti and Jos{\'e} Baselga}, journal={Clinical cancer research : an official journal of the American Association for Cancer Research}, year={2016}, volume={22 8}, pages={2009-19} }